Principal Financial Group Inc. Trims Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Principal Financial Group Inc. lessened its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 7.4% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 202,017 shares of the company’s stock after selling 16,155 shares during the period. Principal Financial Group Inc.’s holdings in Amphastar Pharmaceuticals were worth $9,804,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its stake in Amphastar Pharmaceuticals by 70.0% in the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after buying an additional 273 shares in the last quarter. Innealta Capital LLC acquired a new position in Amphastar Pharmaceuticals during the 2nd quarter worth about $55,000. Blue Trust Inc. boosted its position in Amphastar Pharmaceuticals by 23.9% in the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after buying an additional 309 shares during the period. Asset Management One Co. Ltd. purchased a new stake in shares of Amphastar Pharmaceuticals during the third quarter worth approximately $78,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Amphastar Pharmaceuticals by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock valued at $85,000 after buying an additional 301 shares during the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $44.16 on Tuesday. The company has a market cap of $2.12 billion, a P/E ratio of 14.77, a price-to-earnings-growth ratio of 0.89 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a one year low of $36.56 and a one year high of $65.92. The business has a fifty day moving average of $48.40 and a two-hundred day moving average of $44.40. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AMPH. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Piper Sandler dropped their price target on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Finally, StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st.

Insider Activity

In other news, EVP Yakob Liawatidewi sold 5,214 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total value of $271,388.70. Following the completion of the transaction, the executive vice president now owns 74,938 shares in the company, valued at $3,900,522.90. This trade represents a 6.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Rong Zhou sold 4,000 shares of Amphastar Pharmaceuticals stock in a transaction on Monday, August 26th. The stock was sold at an average price of $48.35, for a total value of $193,400.00. Following the transaction, the executive vice president now directly owns 118,388 shares of the company’s stock, valued at $5,724,059.80. This trade represents a 3.27 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 31,533 shares of company stock worth $1,571,652 in the last 90 days. 27.10% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.